MedTrace Logo

Prognostic Significance of ctDNA in HL

NCT06263530 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2024-02-16

No results posted yet for this study

Summary

Specific somatic mutations using ctDNA will be analyzed in predefined subgroups of cHL (e.g., age \<60 and ≥ 60 years, EBV). These mutations will be correlated with response to the treatment in the first line, in the relapse, during brentuximab vedotin and/or nivolumab treatment. Circulating tumor DNA will be correlated with the extent of tumor mass and chemo/radiotherapy.

Conditions

  • Prognostic Cancer Model

Sponsors & Collaborators

  • Charles University, Czech Republic

    collaborator OTHER

  • General University Hospital, Prague

    collaborator OTHER

  • University Hospital Olomouc

    collaborator OTHER

  • University Hospital Hradec Kralove

    collaborator OTHER

  • University Hospital, Motol

    collaborator OTHER

  • Interni hematologicka klinika FNKV

    lead NETWORK

Principal Investigators

  • Heidi Mocikova, M.D., Ph.D. · Faculty Hospital Kralovske Vinohrady

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-02
Primary Completion
2023-12-31
Completion
2027-12-31

Countries

  • Czechia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06263530 on ClinicalTrials.gov